A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Clinical trial NCT07506109 · RECRUITING

Trial details

NCT number: NCT07506109
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

BRAF V600E Colorectal Cancer Sintilimab MSS (Microsatellite Stable)Cetuximab Dabrafenib Ipilimumab N01

Start date: 2026-03-01
Primary completion: 2027-12-01
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.